AMRN logo

Amarin Corporation plc

AMRN
Healthcare|Drug Manufacturers - General|IE
$11.61
+0.04 (+0.30%)
Tangible Book / Share
$20.79
Cash / Share
$15.53
Next Earnings Report
Feb 24, 2027
EPS est. -$0.08 · Revenue est. $49.9M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (1)

Jan 2029
Est. completion
Acute Coronary Syndrome
Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
NCT06637657n=5,586

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2025
P3
EPA for Metastasis Trial 2
NCT03428477

Recent Press Releases

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Oct 28, 2026 · GlobeNewsWire
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Oct 25, 2026 · GlobeNewsWire
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Oct 21, 2026 · GlobeNewsWire
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Aug 31, 2026 · GlobeNewsWire
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Aug 28, 2026 · GlobeNewsWire
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Aug 24, 2026 · GlobeNewsWire

SEC Filings (41)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 28, 202610-QQuarterly reportDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Aug 27, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 29, 202610-QQuarterly reportDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
Apr 29, 202610-QQuarterly reportDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 10, 2026ARSAnnual report to holdersDocumentIndex
Apr 10, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 30, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 27, 20268-KMaterial eventDocumentIndex
Mar 2, 202610-KAnnual reportDocumentIndex
Feb 25, 20268-KMaterial eventDocumentIndex
Jan 8, 20268-KMaterial eventDocumentIndex
Oct 29, 202510-QQuarterly reportDocumentIndex
Oct 29, 20258-KMaterial eventDocumentIndex
Oct 22, 20258-KMaterial eventDocumentIndex
Jul 31, 2025EFFECTDocumentIndex
Jul 30, 202510-QQuarterly reportDocumentIndex
Jul 30, 20258-KMaterial eventDocumentIndex
Jul 23, 2025F-6DocumentIndex
Jul 3, 20258-K/AMaterial eventDocumentIndex
Jun 24, 20258-KMaterial eventDocumentIndex
May 15, 20258-KMaterial eventDocumentIndex
May 7, 202510-QQuarterly reportDocumentIndex
May 7, 20258-KMaterial eventDocumentIndex
Apr 29, 20258-KMaterial eventDocumentIndex
Apr 10, 2025ARSAnnual report to holdersDocumentIndex
Apr 10, 2025DEF 14AProxy / shareholder voteDocumentIndex
Apr 9, 20258-KMaterial eventDocumentIndex
Apr 7, 2025PRER14ADocumentIndex
Apr 7, 20258-KMaterial eventDocumentIndex
Mar 28, 2025PRE 14AProxy / shareholder voteDocumentIndex
Mar 28, 20258-KMaterial eventDocumentIndex
Mar 25, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 12, 2025F-6 POSDocumentIndex
Mar 12, 202510-KAnnual reportDocumentIndex
Mar 12, 20258-KMaterial eventDocumentIndex
Dec 18, 20248-KMaterial eventDocumentIndex